Significant unmet needs in obesity therapeutics market

26 April 2023

Obesity is a major public health concern with a significant impact on morbidity, mortality, and healthcare costs worldwide. The obesity therapeutics market is expected to grow as the prevalence of obesity increases, but it is also facing considerable unmet needs.

Despite the anticipated arrival of novel therapies in the next decade, major opportunities remain for pharmaceutical companies to develop drugs for obesity that are longer acting, according to a report by GlobalData, a leading data and analytics company.

GlobalData’s latest report, “ Obesity: Seven-Market Drug Forecast and Market Analysis,” reveals that one of the key unmet needs in the obesity space is for longer-acting therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK